CLINICAL_TRIALS
ClinicalTrials.gov record update
5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06632236
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:52.883691+00:00
- Published At
- 2025-04-25T00:00:00+00:00
- Record Updated At
- 2025-04-25
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Malignant Primary Gliomas", "Glioblastoma Multiform (Grade IV Astrocytoma)", "Diffuse Hemispheric Glioma, H3 G34-Mutant", "Glioblastoma Multiforme (GBM)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-25"- protocolSection.identificationModule.nctId
"NCT06632236"- protocolSection.identificationModule.officialTitle
"5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.